지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Directive 98/44/EC was adopted after a long and constructive debate lasting about ten years in both the Council and the European Parliament. During those negotiations, it emerged as a fact that biotechnological inventions are a sector in full expansion: new techniques of great promise for cures and foodstuffs are becoming established very rapidly, and the European legislator considered it essential not to hamper their development. However, their was a need to establish a sound legal framework which allowed European businesses to develop and market the products and processes deriving from genetic engineering.
The Directive distinguishes between plant and animals which are patentable and plant and animals varieties which are not(Art. 4). The reason for this differentiation lies in the means of achieving the product concerned: a plant or animal variety is generally obtained by essentially biological processes(sexual reproduction observable in nature), while transgenic plants and animals are obtained through non-biological processes forming part of genetic engineering. The human body, at the various stages of its formation and development, is not patentable, as it involves a simple discovery. The same applies to the simple decoding of one of its elements. This exclusion also covers the discovery of a sequence or partial sequence of a gene. However, an element isolated from the human body, including a sequence or partial sequence of a gene, by techniques of identification, purification, characterisation and multiplication, may constitute a
patentable invention, even if the structure of that element is identical to that of a natural element. This type of invention, which is eligible for patent protection, must nevertheless fulfil the classic conditions for patentability, i.e. novelty, inventive step and industrial application.
The Directive distinguishes between plant and animals which are patentable and plant and animals varieties which are not(Art. 4). The reason for this differentiation lies in the means of achieving the product concerned: a plant or animal variety is generally obtained by essentially biological processes(sexual reproduction observable in nature), while transgenic plants and animals are obtained through non-biological processes forming part of genetic engineering. The human body, at the various stages of its formation and development, is not patentable, as it involves a simple discovery. The same applies to the simple decoding of one of its elements. This exclusion also covers the discovery of a sequence or partial sequence of a gene. However, an element isolated from the human body, including a sequence or partial sequence of a gene, by techniques of identification, purification, characterisation and multiplication, may constitute a
patentable invention, even if the structure of that element is identical to that of a natural element. This type of invention, which is eligible for patent protection, must nevertheless fulfil the classic conditions for patentability, i.e. novelty, inventive step and industrial application.
목차
Ⅰ. 서론
Ⅱ. 유럽특허협약과 생명공학 지침
Ⅲ. 유럽연합의 생명공학 지침
Ⅳ. 결론
참고문헌
[Abstract]
참고문헌 (0)
참고문헌 신청이 논문과 연관된 판례 (1)
-
대법원 1991. 11. 12. 선고 90후2256 판결
가. 미생물관련 발명에 대한 특허출원에 있어 구 특허법시행령(1983.11.5. 대통령령 제11254호로 개정된 것) 제1조 제2항 본문은 미생물의 기탁기관을 특허청장이 지정하는 기관으로만 한정하였는바, 그 후 개정된 특허법시행령(1987.7.1. 대통령령 제12199호) 제2조 제1항 본문은 미생물의
자세히 보기
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
첨단과학기술의 지적재산권 보호와 그 과제
과학기술법연구
2006 .01
-
생명공학적 발명의 특허에 관한 문제점
법학논집
2000 .01
-
정규교과를 통한 발명교육 프로그램 개발 연구
실과교육연구
2006 .01
-
미완성 발명과 아이디어의 보호
외법논집
2011 .01
-
유럽연합에서의 생명공학 발명의 법적 보호
한양법학
2013 .11
-
대학의 직무발명규정의 운영에 관한 비판적 고찰 － 대학교수발명의 직무발명 해당성여부를 중심으로 －
경영법률
2011 .01
-
대학교수의 아이디어 유출과 창의 자본에 관한 법적 검토
경영법률
2009 .01
-
발명의 단일성에 관한 고찰
지식재산연구
2007 .12
-
발명교육 네트워크 구축 및 활용 방안
영재교육연구
2001 .04
-
실과 교과에서 발명교육을 위한 프로그램 개발
실과교육연구
2009 .01
-
발명교육 활성화를 위한 지역사회 연계 방안
실과교육연구
2020 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-360-001530412